In fact, rHIgM22 treatment in differentiated oligodendrocytes reduces the activity of ASM, a key mediator for the detrimental effects of ceramide observed in mouse models of MS (genetic or pharmacological inhibition of ASM is protective against lesions in mouse models of MS [54,55,57]). The gene discussed is SMPD1; the disease is myeloid sarcoma.